Lobe Sciences Announces That Its Shares Will Trade on the OTCQB Market in the United States Pharmaceutical Investing
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough Pharmaceutical Investing
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization Pharmaceutical Investing
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy Pharmaceutical Investing
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma Pharmaceutical Investing
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma Pharmaceutical Investing
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma Pharmaceutical Investing
Bristol Myers Squibb's Breyanzi Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results Pharmaceutical Investing
Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman Pharmaceutical Investing
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results Pharmaceutical Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
